Status:
RECRUITING
Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborating Sponsors:
Children's Hospital of Chongqing Medical University
Conditions:
Respiratory Distress Syndrome
Preterm Birth
Eligibility:
All Genders
1-24 years
Brief Summary
In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal m...
Detailed Description
To date, PS is not recommended to adult and pediatric ARDS. Meantime, systematic review indicates that PS does not demonstrate statistically significant beneficial effects on reducing the mortality an...
Eligibility Criteria
Inclusion
- Eligibility requirements for neonates were as follows:
- The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth
- The neonates will be diagnosed with NRDS or NARDS
- The neonates will be at least administrated one dose of surfactant
Exclusion
- one of the following criteria will be needed
- major congenital anomalies
- chromosomal abnormalities
- upper respiratory tract abnormalities
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04777760
Start Date
January 1 2021
End Date
December 31 2026
Last Update
July 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chen
Chongqing, Chongqing Municipality, China, 400042